1. Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis 
Xin Hui S Chan, MRCP, Yan Naung Win, MPH, Laura J Mawer, MBBChir, Jireh Y Tan, MS, Prof Josep Brugada, PhD, Prof Nicholas J White, FRS 
The Lancet Infectious Diseases 
Volume 18, Issue 8, Pages (August 2018)
DOI: /S (18)
Copyright © 2018 World Health Organization Terms and Conditions

2. Figure 1 Study selection
DP=dihydroartemisinin–piperaquine. MSAT=mass screen and treat. IPT=intermittent preventive therapy. IST=intermittent screen and treat. SMC=seasonal malaria chemoprevention. PK=pharmacokinetic.
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 World Health Organization Terms and Conditions

3. Figure 2
Number of individuals exposed to, and deaths after, dihydroartemisinin–piperaquine
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 World Health Organization Terms and Conditions

4. Figure 3 Causes of death after dihydroartemisinin–piperaquine
Data presented by age group and treatment indication.
The Lancet Infectious Diseases  , DOI: ( /S (18) )
Copyright © 2018 World Health Organization Terms and Conditions